SLC5A2 and atrial fibrillation: European guidelines undoubtedly recommend the use of HF disease‐modifying treatment, including, renin‐angiotensin system inhibitors, beta‐blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, as soon as possible to reduce morbidity and mortality, but also anticoagulation in AF patients, preferably with direct oral anticoagulants.15